Short-term Intensive Immunosuppression: A Randomized, Three-arm Study of Intravenous Pulse Methylprednisolone and Cyclophosphamide in Macular Serpiginous Choroiditis

REFERENCES

• Venkatesh P, Gogia V, Shah B, et al. Patterns of uveitis at the Apex Institute for Eye Care in India: Results from a prospectively enrolled patient data base (2011–2013). Int Ophthalmol. 2016;36:365–372.
   PubMed Web of Science ®Google Scholar
• Biswas J, Narain S, Das D, et al. Pattern of uveitis in a referral uveitis clinic in India. Int Ophthalmol. 1996-1997;20:223–228.
   PubMed Web of Science ®Google Scholar
• Hooper P, Kaplan H. Triple agent immunosuppression in serpiginous choroiditis. Nussenblatt RB, discussion. Ophthalmology. 1991;98:944–952.
   PubMed Web of Science ®Google Scholar
• Sobacı G, Bayraktar Z, Bayer A. Interferon alpha-2A treatment for serpiginous choroiditis. Ocul Immunol Inflamm. 2006;13:59–66.
   Web of Science ®Google Scholar
• Venkatesh P, Gogia V, Gupta S, et al. Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy. Indian J Ophthalmol. 2015;63:318–322.
   PubMed Web of Science ®Google Scholar
• Munteanu G, Munteanu M, Zolog I. Serpiginous choroiditis – clinical study. Oftalmologia. 2001;52:72–80.
   PubMedGoogle Scholar
• Hardy RA, Schatz H. Macular geographic helicoid choroidopathy. Arch Ophthalmol. 1987;105:1237–1242.
   PubMedGoogle Scholar
• Saurabh K, Panigrahi PK, Kumar A, et al. Profile of serpiginous choroiditis in a tertiary eye care centre in eastern India. Indian J Ophthalmol. 2013;61:649–652.
   PubMed Web of Science ®Google Scholar
• Abrez H, Biswas J, Sudharshan S. Clinical profile, treatment and visual outcome of serpiginous choroiditis. Ocul Immunol Inflamm. 2007;15:325–335.
   PubMed Web of Science ®Google Scholar
• Wu JS, Lewis H, Fine SL, et al. Clinicopathologic findings in a patient with serpiginous choroiditis and treated choroidal neovascularization. Retina. 1989;9:292–301.
   PubMed Web of Science ®Google Scholar
• Lim WK, Buggage RR, Nussenblatt RB. Serpiginous choroiditis. Surv Ophthalmol. 2005;50:231–244.
   PubMed Web of Science ®Google Scholar
• Hoyng C, Tilanus M, Deutman A. Atypical central lesions in serpiginous choroiditis treated with oral prednisone. Graefes Arch Clin Exp Ophthalmol. 1998;236:154–156.
   PubMed Web of Science ®Google Scholar
• Laatikainen L, Tarkkanen A. Failure of cyclosporin A in serpiginous choroiditis. J Ocul Ther Surg. 1984;3:280–283.
   Google Scholar
• Secchi AG, Tognon MS, Maselli C. Cyclosporine-A in the treatment of serpiginous choroiditis. Int Ophthalmol. 1990;14:395–399.
   PubMed Web of Science ®Google Scholar
• Araujo AA, Wells AP, Dick AD, et al. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol. 2000;84:979–982.
   PubMed Web of Science ®Google Scholar
• Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98:944–951.
   PubMed Web of Science ®Google Scholar
• Sahin OG. Long-term cyclophosphamide treatment in a case with serpiginous choroiditis. Case Rep Ophthalmol. 2010;1:71–76.
   PubMedGoogle Scholar
• Sahu DK1, Rawoof A, Sujatha B. Macular serpiginous choroiditis. Indian J Ophthalmol. 2002;50:189–196.
   PubMedGoogle Scholar
• Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718–722.
   PubMed Web of Science ®Google Scholar
• De Groot K, Harper L, Jayne DR, et al.; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–680.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Halkiadakis I, Papaeythymiou-Orchan S, et al. Intravenous pulse methylprednisolone therapy for, acute treatment of serpiginous choroiditis. Ocul Immunol Inflamm. 2006;14:29–33.
   PubMed Web of Science ®Google Scholar
• Hari P, Srivastava RN. Pulse corticosteroid therapy with methylprednisolone or dexamethasone. Indian J Pediatr. 1998;65:557–560.
   PubMedGoogle Scholar
• Haga HJ, D’Cruz D, Asherson R, et al. Short term effects of intravenous pulses of Cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis. 1992;51:885–888.
   PubMed Web of Science ®Google Scholar
• Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short term safety. Ophthalmology. 2004;111:960–965.
   PubMed Web of Science ®Google Scholar
• Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76:377–384.
   PubMed Web of Science ®Google Scholar
• Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248–257.
   PubMed Web of Science ®Google Scholar
• Yee CS, Gordon C, Dostal C, et al. EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis. 2004;63:525–529.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Simpson J, Neuwelt CM. Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol. 1997;81:130–132.
   PubMed Web of Science ®Google Scholar
• Martin-Suarez I, D’Cruz D, Mansoor M, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997;56:481–487.
   PubMed Web of Science ®Google Scholar
• Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351–358.
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549–557.
   PubMed Web of Science ®Google Scholar
• Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–625.
   PubMed Web of Science ®Google Scholar
• Suelves AM, Arcinue CA, González-Martín JM, et al. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology. 2013;120:1201–1209.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Jabs DA, Tessler HH, et al. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology. 2002;109:1506–1513.
   PubMed Web of Science ®Google Scholar
• Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990;29:371–374.
   PubMed Web of Science ®Google Scholar
• Das S, Giri PP, Roy AK. Dexamethasone- cyclophosphamide pulse in collagen vascular diseases: An observation. Indian Dermatol Online J. 2011;2:10–12.
   PubMedGoogle Scholar
• Mandapati JSR, Mehta AK. Intraocular pressure variation in patients on long-term corticosteroids. Indian Dermatol Online J. 2011;2:67–69.
   PubMedGoogle Scholar
• De Ridder D, van Poppel H, Demonty L, et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol. 1998;159:1881–1884.
   Google Scholar
• Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13:673–678.
   PubMed Web of Science ®Google Scholar